Chronoscale Holdings Corp quarterly report, Q2 FY2013

Filing and reporting period

The supplied filing is a Form 10-Q for PN Med Group Inc., not Chronoscale Holdings Corp. It covers the quarter and six months ended September 30, 2012; the company was incorporated January 30, 2012 and identifies itself as a development-stage company. The filing metadata’s “2012 Q2” label does not match the stated quarter-end, so the period should be verified.

PN Med planned to distribute medical supplies and equipment in Chile but reported that it had not commenced operations or generated revenue.

Financial results and liquidity

MetricThree months ended Sept. 30, 2012Six months ended Sept. 30, 2012
Revenue$0$0
Operating expenses$1,252$6,147
Net loss$1,252$6,147
Operating cash flowNot separately provided$(9,897)

At September 30, 2012, cash was $12,727, compared with $8,443 at March 31, 2012. Current liabilities were $18,531, comprising $750 of accrued expenses and $17,781 due to a shareholder/officer. The shareholder loans are unsecured, non-interest-bearing, and due on demand. The resulting working-capital deficit was $5,804; stockholders’ equity was also negative $5,804, versus positive equity of $343 at March 31.

Six-month financing cash inflow was $14,181, consisting of additional shareholder loans; there was no investing cash flow. No interest or income taxes were paid. The filing reports no material market-risk disclosure.

Changes, outlook, and risks

  • Six-month expenses produced a $6,147 net loss, while the company remained pre-revenue. Accumulated development-stage deficit increased to $10,804.
  • Management said existing funds and anticipated advances or debt were expected to fund operations for the next three months, but also said additional funding would be needed within 12 months. No specific financing plan or financing arrangement was in place; management anticipated seeking equity financing and possibly short-term director loans.
  • Management expects start-up, inventory, and marketing costs to increase. Financing may be unavailable or unacceptable, and new equity or convertible debt could dilute shareholders or carry senior rights.
  • The filing’s going-concern note cites no revenue, limited working capital, and dependence on additional investment capital; it says there is no assurance the company can obtain funding or remain viable. Management also references substantial doubt expressed in the auditor’s review report for the March 31, 2012 statements.
  • Management concluded disclosure controls and procedures were not effective as of September 30, 2012. It reported no material change in internal control over financial reporting during the quarter.
  • The company reported no material subsequent events through issuance and no known pending or threatened legal proceedings.

Important facts to verify

  • Confirm the issuer and period: the supplied document names PN Med Group Inc. and reports September 30, 2012, unlike the request metadata.
  • Reconcile the balance-sheet presentation: total assets are shown as $12,727 and liabilities plus equity calculate to $12,727, but the displayed “Total Liabilities and Stockholder’s Equity (Deficit)” is $5,229.
  • Assess the company’s ability to fund operations and meet the shareholder loan, which is due on demand, given its cash shortfall against current liabilities and lack of committed financing.
  • Review the disclosed ineffective controls and the referenced going-concern warning when evaluating reporting reliability and viability.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.